XSCID
XSCID is an immunodeficiency in which both cell-mediated and humoral immunities are absent (1, 3, 12, 14, 18, 33, 41, 56, 57) . This absence can be either partial or complete, and if it is not treated by bone marrow transplantation by the age of 2 years, it is usually fatal. Familial analyses have confirmed the X-linked inheritance of this disease. Through a process known as lyonization, random inactivation of either the maternally or paternally derived X chromosome occurs in all cells of females. Carrier mothers of male patients with XSCID, however, do not show the normal pattern of random X-chromosome inactivation in their mature T cells, B cells, and NK cells and, instead, express nonrandom inactivation of the defective X chromosome (5, 11, 62) . This indicates that the lymphocytes of the maternal XSCID carriers require the normal X chromosome in the activated (expressed) state for their function. Through detailed family studies and linkage analyses, the XSCID gene was subsequently localized to the long arm of the X chromosome at position q13 (Xq13) (3, 6, 23, 36) . By identifying markers near the Xq13 locus, linkage analyses and analyses of X-chromosome inactivation patterns can be used for prenatal counseling for potential carriers. Although this method of identifying maternal carriers is reliable, 40% of all cases of XSCID in male patients are derived from spontaneous mutations in their X chromosome and hence could not have been identified through prenatal screening since their mothers would not have been identified as carriers (12, 33) .
The actual molecular basis of this immune disease remained uncertain until the separate teams of Noguchi et al. (30) and Puck et al. (35) demonstrated that the IL-2R ␥ chain also mapped to Xq13 and that most patients with XSCID exhibited some mutation in the gene for the IL-2R ␥ chain. Hence, the development of XSCID is due to expression of mutated dysfunctional IL-2R ␥ chains or nonexpression of IL-2R␥ altogether, because the mutation may affect mRNA production or stability. The individual mutations range throughout the sequence of the ␥ chain and affect either binding of IL-2 or docking of signal modalities associated with IL-2 (15; see reference 56 for a current summary of mutation locations). This discovery emphasizes the importance of the IL-2R ␥ chain in immune development and function, although clarification of its vast effect was required. However, even with this additional knowledge regarding the molecular basis of XSCID, a practical mechanism for screening potential carriers of IL-2R␥ mutations remains complex and thus requires reevaluation of what is known about this disease, beginning with reviewing IL-2 and the dynamics of its receptor complex.
DESCRIPTION OF THE IL-2R COMPLEX
IL-2Rs exist in high-, intermediate-, and low-affinity forms. The IL-2R was initially characterized as a single receptor component (55 kDa), known as the ␣ chain. Subsequent studies documented involvement of a second subunit of 70 to 75 kDa, designated IL-2R␤. It was then concluded that IL-2Rs existed in low-, intermediate-, and high-affinity forms consisting of ␣, ␤, and ␣␤ subunits, respectively (Table 1) (24, 45, 46, 53, 59, 60) .
When the cDNA for the IL-2R ␤ chain was cloned and isolated IL-2R ␤ chains were expressed on the membranes of nonlymphoid cells, they were unable to bind IL-2 (11, 25, 38, 54) . This suggested that a third receptor component absent from nonlymphoid cells may be an essential part of the intermediate-affinity receptor. Several teams began searching for a third receptor component for IL-2, identifying putative IL-2R-associated molecules (49) . Sugamura and colleagues (48) successfully identified a 64-kDa molecule as the third component of the IL-2R. This third IL-2R subunit was designated the IL-2R ␥ chain and is involved in the formation of functional intermediate-affinity receptors on NK cells from IL-2-treated cancer patients. Furthermore, the level of IL-2R␥ protein expression, and not the IL-2R ␤ chain, determined the number of intermediate-affinity receptors on NK cells (51, 58) .
The current model for IL-2Rs includes the ␥ chain as a component of both high-and intermediate-affinity receptor complexes ( Table 1) . The IL-2R ␤ chain is also a component of high-affinity receptors, while the IL-2R ␣ chain exists either alone as the low-affinity receptor or combines with IL-2R␤ and IL-2R␥ to form high-affinity receptors. Pseudo-high-affinity ␣␤ complexes at equilibrium bind IL-2 with an affinity approaching those of ␣␤␥ high-affinity complexes, but they are distinct from true high-affinity receptors in that IL-2 dissociates more rapidly from this receptor form than from true high-affinity receptors. This latter observation implicates the ␥ chain in regulating receptor function by slowing the dissociation of IL-2 from the receptor complex. Prolongation of IL-2 dissociation from the receptor complex appears essential, since receptors deficient in the ␥ chain are incapable of internalization and interactions with signaling modalities (48) .
PLEOMORPHISM OF THE ␥ CHAIN
Given the correlation of ␥-chain defects with XSCID development, the critical role of the ␥ chain in immune development required clarification, since IL-2 itself did not appear to be an essential component of this process (7, 31, 61) . This point was established in studies of IL-2 knockout mice which lack the ability to produce IL-2 yet do not develop an XSCID-like immune deficiency (44) . Instead, these IL-2-deficient animals initially develop a fairly intact cellular immune system but go on to develop histopathologic changes remarkably similar to those seen in chronic ulcerative colitis. The IL-2R ␥ chain must therefore be involved in some role critical for immune development beyond its involvement in IL-2 recognition. One potential role is as a receptor component for other IL-2-related cytokines.
The potential for the ␥ chain to be a shared component for other cytokines was not an entirely new concept because IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF) share a receptor component, the GM-CSF R ␤ chain (known as ␤ c ) (26) . The laboratories of Leonard (29, 43) and Sugamura (21) established that both IL-4 and IL-7 (cytokines required for immune development and related structurally to IL-2) require the IL-2R ␥ chain within their receptor complexes for characteristic binding properties and cellular responses to occur. More recently, the IL-2R ␥ chain has been implicated in the formation of receptors for IL-9, IL-15, and most likely, IL-11 and IL-13. The IL-2R ␥ chain has now been renamed the ␥-common chain, or ␥ c , emphasizing its role as a shared receptor component.
The sharing of ␥ c by several cytokines, all essential in immune development, accounts for the profound degree of immune impairment in patients with XSCID. The myeloid lineage, however, is not affected, because patients with XSCID appear to have normal monocyte representation. Yet monocytes do require IL-2 at some levels of activity, and hence would also require normal ␥ c expression. When monocyte populations in XSCID carriers are analyzed for nonrandom X inactivation, the results are mixed; some data indicate that nonrandom X inactivation can occur in monocytes in some XSCID carriers (18) , while other data do not show nonrandom X inactivation in monocytes (5) . Further clarification regarding the nature of monocytes in XSCID carriers and patients with XSCID will be pertinent to understanding the penetrance of the influence of ␥ c on monocyte development and activity. In addition, defining the role of ␥ c in stem cell generation (including the myeloid lineage) is essential if gene therapy for this disease is to be considered. In order to select hematopoietic stem cells and introduce the correct ␥ c gene into them, it will be necessary to know at what stage of immune development this gene becomes involved so that the appropriate population of stem cells is targeted for gene therapy.
SCREENING ASSAYS FOR XSCID
Although gene therapy for XSCID is attractive, a more urgent focus is on the development of an efficient and reliable screening method for XSCID carriers and the identification of patients with XSCID. One source of reagents for the development of such an assay are antibodies against ␥ c , which are listed in Table 2 . These reagents have been essential in clarifying some of the earlier work on IL-4 and IL-7 receptors, allowing coimmunoprecipitations to be done. They have also proven crucial in beginning to define ␥ c expression among different subsets of lymphocytes.
There are several potential problems with using a proteinbased assay, the most prevalent of which is that several of the ␥ c mutations defined in patients with XSCID are simple point mutations that may or may not alter protein conformation in a manner that would allow differential detection of mutated ␥ c from the wild type with the use of these antibodies. Second, even for ␥ c deletion mutations, if only the cytoplasmic domain of ␥ c is affected, it would not be detected by antibodies recognizing extracellular domains unless the assay reveals size differences as well. Third, prevention of the disease would be more favorable than detection of it after development, raising the necessity for an easy screening method for identifying carriers through their inheritance of a dysfunctional ␥ c gene copy. Carrier detection assays, however, will still miss 40% of the patients with XSCID in whom the disease is attributed to spontaneous mutations. Furthermore, assays that identify ab- normal ␥ c proteins could not be used to identify carriers because the defective X chromosome in those carriers is inactive, and hence, no defective ␥ c protein is produced. Assays based on DNA are thus far the best approach because both patients with XSCID and carriers could be identified by the same test (see Table 3 for summary of methods). One molecular approach to identifying carriers on the basis of DNA analysis could involve sequencing the entire gene in all potential carriers. Although possible, the cost, labor, and time involved make this an impractical approach. It would be much easier if the ␥ c defects were clustered to form a ''hot spot'' so that only a portion of the gene would need to be sequenced. Two such hot spots, C 690 and C 879 , have recently been identified by Pepper et al. (32) . Both of these hot spots are CpG dinucleotides known to be C3T transversion sites. Since it is suggested that mismatches in these two positions may represent up to 15% of all human SCID cases, it may be pertinent, then, as a first step, to screen carriers and/or to identify affected males by sequencing these regions. However, a superior method which does not require sequencing has been adapted by Puck (34) ; it is called single-strand conformation polymorphism and identifies XSCID carriers and affected males in a time-efficient manner. In this assay, primers flanking each exon of the ␥ c gene are used to amplify DNA samples. The denatured products are separated on modified acrylamide gels which allow for different migration patterns of even single-base mutations within the exon in comparison with the wild-type exon product. It is then fairly easy to sequence that particular exon to determine what the specific mutation is, although it is not necessary if the assay was used solely for screening.
Another potential method that uses DNA as the initial material is called the protein truncation test and could be modified for use in screening carriers (40) . In this assay, active DNA is amplified and translated into protein by using an in vitro rabbit reticulocyte system. The full-length protein product is detected in a sandwich enzyme-linked immunosorbent assay by using one antibody against the carboxy terminus of the protein and one antibody against the amino terminus of the protein.
Hence, this assay would be very effective in screening for X-SCID patients whose ␥ c mutation resulted in truncations of the protein. However, this method could not detect point mutations or deletions and would also need to be modified so that inactive DNA sequences could be read, allowing carriers to be screened. Hence, single-strand conformation polymorphism remains the most efficient method to date for identifying X-SCID carriers and patients with XSCID.
Aside from the development of screening assays for XSCID, one diagnostic difficulty has been to distinguish males with XSCID from males exhibiting an autosomal recessive form of SCID because both patients would have depleted T cells and heightened B-cell numbers. The X-chromosome inactivation in their mothers clarified some of this distinction in that in 10 of 22 patients with sporadic SCID, the SCID was found to be X linked (37) . However, X-chromosome inactivation in the remaining 12 of 22 patients could be the result of new ␥ c gene mutations in patients with XSCID or inheritance of other (autosomal) genetic defects that cause the SCID clinical spectrum. A separate study by Conley et al. (4) showed that 7 of 16 patients had carrier mothers. Perhaps the identification of genes which could account for some of these sporadic SCID cases would eventually lead to our ability to account for several forms of SCID which are currently considered sporadic, as XSCID once was.
JAK3: POTENTIAL TARGET FOR OTHER TYPES OF SCID
JAK proteins are a group of the Janus family kinases that are associated with activation of several different cytokines (Table 4) (13, 17, 19, 27, 63) . Hence, if a receptor complex is engaged by its specific cytokine, one or more JAK proteins are found to be associated with it (Fig. 1) . Many of these JAK proteins show ubiquitous expression, even though their levels are significantly enhanced upon receptor activation. However, JAK3 is different, because it is specifically expressed in lymphocytes, monocytes, and granulocytes but not most other cell types. Furthermore, its protein levels are inducible with IL-2, IL-4, IL-7, and IL-9. Since these cytokines all utilize ␥ c , teams working on this particular JAK hypothesized that it may be a ␥ c -specific kinase (27, 42) . Subsequent studies documented the interaction of JAK3 with ␥ c -containing receptor complexes.
This establishes JAK3 as a link between cellular responses and engagement of ␥ c with cytokines critical to immune development and functions. Hence, mutations in JAK3 could virtually result in the same diagnostic deficiencies seen in patients with XSCID caused by ␥ c mutations. Further clarification of this possibility may indeed lead to the discovery of another group of explainable sporadic SCID.
IL-15: POTENTIAL TARGET FOR OTHER TYPES OF SCID
IL-15 is a cytokine which is structurally related to IL-2. Its activities include functions that were once thought to be ex- clusive to IL-2, such as the ability to stimulate T-cell proliferation, generate LAK activity, and stimulate NK cell cytotoxicity (2, 10). As such, it was thought that IL-15 might also utilize components of the IL-2 receptor. This was explored by proliferation and binding assays in which selected antibodies known to inhibit binding of IL-2 to its specific receptor components were tested with IL-15 (the results are summarized in Table 5 ). These experiments have confirmed that the receptor complex for IL-15 involves both the IL-2R ␤ chain and the ␥ c chain (2, 9, 10), which may provide insight into the somewhat unanticipated functional immunity observed in IL-2 knockout mice. These IL-2-deficient mice may develop some functional immunity because IL-15 is still present and is capable of supporting many of the functions that IL-2 does through the use of IL-2R␤␥ complexes. However, it is still unclear how IL-15 fits into the scheme of immune development and function and whether its activities are meant to coincide with those of IL-2 or to have distinct functions. A testable hypothesis is that IL-15 functions both independently and in concert with IL-2, depending on the composition of the cell surface receptor complexes. Evidence exists to suggest that there may be an IL-15-specific receptor component (Fig. 2) (27) . If so, IL-15 may have specific functions that would not be mediated by IL-2. Another distinction between IL-2 and IL-15 lies in the fact that IL-15 appears to be produced by many cell types and tissues (13) . Perhaps IL-15 functions to prime the T-cell response in some fashion so that encountering another cytokine (such as IL-2) will allow for a faster response and, hence, would operate in concert with IL-2.
This becomes a critical point within the realm of XSCID because the expression of IL-15 mRNA in many tissues sug-FIG. 1. IL-2R complex formation and involvement of JAKs. In the absence of IL-2, the IL-2R ␤ chain is associated with JAK-1, while the IL-2R ␥ chain is associated with JAK-3, although the complex between the IL-2R components is not formed. In the presence of IL-2, the receptor components for IL-2 form a complex in which JAK-1 and JAK-3 undergo activation via phosphorylation. In response to JAK-1 and JAK-3 activation, both the RAS pathway and STAT pathway (13) are engaged, leading to the appropriate stimulation of the cell. 
a Activation in response to particular cytokines as indicated is marked as with a plus sign, while a lack of involvement in response to particular cytokines as indicated is marked as a minus sign. The summary of JAKs involved in each cytokine response was taken from numerous publications (13, 17, 19, 27, 42, 63) . Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; Tyk-2, tyrosine kinase-2; CNTF, ciliary neutrophic factor; LIF, leukemia inhibitory factor; OSM, oncostatin M; IFN, interferon. Blocking of binding or lack of proliferation in response to particular stimulus is indicated by a minus sign, while the inability to block binding or inhibit proliferation in response to particular stimulus is indicated by a plus sign. The data summarized here were extracted from several sources (2, 9, 10, 39, 50, 55) .
b IL-15 binding is blocked only partially (range, 40 to 75%). 
CONCLUSIONS
By dissecting the cause of a disease, we can gain much knowledge that can be used to further our understanding of normal biologic function as well as to generate advancements in therapeutic or diagnostic approaches. This has certainly been true in relation to XSCID, which has recently been characterized as a direct consequence of genetic mistakes in ␥ c . With this molecular characterization of XSCID now in hand, methods that use this knowledge can be developed to identify the disease, correct the defect, and more importantly, screen for potential carriers.
All three of these potential clinical applications, diagnosis, treatment, and screening, have proven to be problematic for two primary reasons. First, even though two hot spots have been identified, the families affected by non-hot spot mutations can occur throughout the gene for ␥ c and may be expressed as various molecular modifications, some of which are detectable and some of which are not so easily detectable. Second, testing of ␥ c protein levels or functions will not be informative in detecting carriers because of the nonrandom X-chromosome inactivation. Thus, the methodology currently in hand is so cumbersome and involved that quick screening is out of reach except in the case of single-strand conformation polymorphism. However, even this methodology is challenging and will require a tremendous amount of cooperation between clinicians and researchers familiar with the technique and its interpretation before it can be used in a standard fashion.
What makes the development of screening methods even more frustrating is that the SCID family of disease as a whole is caused by a spectrum of various genetic errors, each of which may hinder immune development or function at some distinct level or physiologic step. Thus, SCID may be the clinical manifestations of many distinct molecular defects, only some of them, such as XSCID, being characterized to date (1, 4, 12, 14, 37, 56, 57) . This minireview addressed only two such possibilities, JAK3 and IL-15. Because the causative molecular defects for many patients with SCID remain incompletely defined, it seems that screening of distant family members or healthy unrelated individuals for carrier status will require a great deal of effort. Nonetheless, the knowledge gained from the study of these complex defects may provide insight into future therapies, so that, while elusive, these are goals well worth pursuing.
